EU patient information proposal "too pro-industry", MEPs told
This article was originally published in Scrip
A European Parliament workshop today on the information to patients proposal produced a wealth of interesting comments and criticisms, but above all a general feeling that the draft legislation is too "pro-industry" and will need to be substantially amended if it is to stand any chance of approval.
You may also be interested in...
EU and UK regulators are vying for vaccine filings, and the EMA will consider changing the terms of the marketing authorization for remdesivir after a WHO panel advised against its use in COVID-19. An Austrian biotech firm is investigating the prophylactic potential of a carrageenan-based spray.
Health activists are stepping up the pressure on COVID-19 vaccine companies to share their IP and reveal their costs, while the European Medicines Agency has published regulatory guidance advising vaccine developers to aim for a point estimate of efficacy of at least 50%.
The EU has ambitious plans for dealing with future health crises, bolstering needs-led innovation, improving access to medicines, and tackling drug shortages.